Cidara Therapeutics Inc (CDTX) - Total Assets
Based on the latest financial reports, Cidara Therapeutics Inc (CDTX) holds total assets worth $518.65 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Cidara Therapeutics Inc (CDTX) shareholders funds for net asset value and shareholders' equity analysis.
Cidara Therapeutics Inc - Total Assets Trend (2013–2024)
This chart illustrates how Cidara Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Cidara Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Cidara Therapeutics Inc's total assets of $518.65 Million consist of 98.1% current assets and 1.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.4% |
| Accounts Receivable | $1.69 Million | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Cidara Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Cidara Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cidara Therapeutics Inc's current assets represent 98.1% of total assets in 2024, a decrease from 98.5% in 2013.
- Cash Position: Cash and equivalents constituted 88.4% of total assets in 2024, down from 92.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Cidara Therapeutics Inc Competitors by Total Assets
Key competitors of Cidara Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Cidara Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.62 | 3.54 | 1.48 |
| Quick Ratio | 4.62 | 3.54 | 1.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $346.98 Million | $112.43 Million | $18.63 Million |
Cidara Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Cidara Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.48 |
| Latest Market Cap to Assets Ratio | 32.41 |
| Asset Growth Rate (YoY) | 220.4% |
| Total Assets | $214.80 Million |
| Market Capitalization | $6.96 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Cidara Therapeutics Inc's assets at a significant premium (32.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Cidara Therapeutics Inc's assets grew by 220.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cidara Therapeutics Inc (2013–2024)
The table below shows the annual total assets of Cidara Therapeutics Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $214.80 Million | +220.45% |
| 2023-12-31 | $67.03 Million | +41.15% |
| 2022-12-31 | $47.49 Million | -36.96% |
| 2021-12-31 | $75.33 Million | +24.66% |
| 2020-12-31 | $60.42 Million | -12.40% |
| 2019-12-31 | $68.98 Million | -12.81% |
| 2018-12-31 | $79.11 Million | +0.10% |
| 2017-12-31 | $79.03 Million | -26.11% |
| 2016-12-31 | $106.96 Million | -2.74% |
| 2015-12-31 | $109.97 Million | +351.64% |
| 2014-12-31 | $24.35 Million | +12014.43% |
| 2013-12-31 | $201.00K | -- |
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more